Page 148 - ESHRE2019
P. 148

 Limitations of immunological assays
  Baker, 2015
Rizner T.L. Et al.
Problems with antibodies:
 cross reactivity,
 batch to batch variations,  lack of validation. Problems with ELISA assays?
Rizner et al. 2016 31
 Serum proteomics in search for biomarkers of endometriosis
       Study
Method
Group
Findings
Diagnostic accuracy
Dutta et al. 2016
2DE, 2D‐ DIGE MALDI TOF‐MS
280 patients (52 I, 52 II, 53 III, 52 IV) 79 control heatlhy women, secretory phase
2DE:HP, LRG1 APOA1, CLU, C4B 2D‐DIGE:
101 protein spots p< 0.05 AFA, HP, ITIH4, IGKC, ALB, TRIM5, A1BG
 stages I, II, III and IV
haptoglobulin (HP) SEN: 80‐92%
SP: 76‐96%
AUC: 0.78‐0.96
Ig  chain C region (IGKC) SEN: 68‐84%
SP: 88‐92%
AUC: 0.75‐0.93 alpha‐1‐glycoprotein (A1BG) SEN: 80‐92%
SP: 48‐80% AUC: 0.62‐0.92
32
     146
143
 





































































   146   147   148   149   150